Photo by nullplus from unsplash
Hypomethylating agents remain the current standard of care for patients with higher‐risk myelodysplastic syndromes. Adès et al. report outcomes from a randomised ‘pick‐a‐winner’ study design that examined the addition of… Click to show full abstract
Hypomethylating agents remain the current standard of care for patients with higher‐risk myelodysplastic syndromes. Adès et al. report outcomes from a randomised ‘pick‐a‐winner’ study design that examined the addition of either lenalidomide, valproic acid or idarubicin in combination with azacitidine, compared to azacitidine alone.
Keywords:
higher risk;
myelodysplastic syndromes;
winner;
risk myelodysplastic;
enhancing chances
Journal Title: British Journal of Haematology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: British Journal of Haematology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!